Physician profile
Teketa Hall
NPI 1649777301
$809.75
in general payments reported to CMS, 2019-2025
19 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $89.03 · 2023: $17.74 · 2024: $256 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $100.50 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $98.01 | 2024 | |
| Sumitomo Pharma America, INC. | $93.51 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $83.52 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $53.44 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.01 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novo Nordisk INC | $50.88 | 2025 | Ozempic |
| Cmp Pharma, INC. | $31.98 | 2021 | |
| Abbvie INC. | $28.67 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.31 | 2024-2025 | Caplyta |
| Dexcom, INC. | $24.84 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $24.68 | 2025 | |
| Lilly USA, LLC | $23.83 | 2025 | Mounjaro |
| Ucb, INC. | $23.59 | 2024 | Briviact |
| Athena Bioscience, LLC | $21.89 | 2025 | Nexiclon Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21.80 | 2025 | Freestyle Libre |
| Smith+Nephew, INC. | $18.55 | 2024 | Collagenase Santyl |
| Esperion Therapeutics, INC. | $14.87 | 2022 | |
| Exact Sciences Corporation | $13.87 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teketa Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.